The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study by Elena Raffetti et al.
Raffetti et al. Infectious Agents and Cancer  (2015) 10:34 
DOI 10.1186/s13027-015-0032-yRESEARCH ARTICLE Open AccessThe predictive role of NLR and PLR for solid
non-AIDS defining cancer incidence in
HIV-infected subjects: a MASTER cohort study
Elena Raffetti1*, Francesco Donato1, Francesco Castelli2, Franco Maggiolo3, Giampiero Carosi4
and Eugenia Quiros-Roldan2Abstract
Background: The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), two low cost,
routinely available inflammatory indices, have been found to be associated with risk of death in patients with
solid cancer, in both general population and HIV-positive subjects. However, no study investigated the role of
NLR and PLR as predictive of cancer incidence so far.
Methods: The aim of our study was to assess the association of PLR and NLR with risk of developing solid non-AIDS
defining cancer (NADC) in HIV-infected subjects. We conducted a multicenter Italian cohort study from 2000 to 2012
including HIV-infected subjects naïve at antiretroviral treatment at enrollment. The associations of NLR and PLR with
NADC incidence were evaluated by univariate and multivariate analyses using both time independent and time
dependent Cox proportional hazard models.
Results: Thirteen thousand five hundred fifty-nine patients (73.3 % males) with a mean age of 36.0 years (SD 10.0)
were included. The median (inter-quartile range) of NLR and PLR at baseline were 1.47 (1.03–2.17) and 109.9
(79.6–155.3), respectively. During a median follow-up of 3.9 years, 337 subjects had a first diagnosis of solid NADC. The
crude and age- and gender-standardized incidence rates were 3.57 and 3.91 per 1000 person-years, respectively. No
statistically significant association was found between NLR and PLR and NADC incidence, using multivariate models,
including also time-dependent Cox models with a cubic-spline for NLR and PLR.
Conclusion: This study does not sustain the hypothesis that NRL and PLR may be useful for predicting the risk of
cancer in HIV positive subjects.
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Chronic inflammation is thought to be a key mediator of
cancer through the mobilization of transcription factors
and inflammatory mediators, as recruitment of inflam-
matory cells, including neutrophils and megakaryocytes,
causes neutrophilia and thrombocytosis on the cancer
site, leading to tumor promotion, invasion, and metasta-
sis [1]. Accordingly, the serum level of C-reactive pro-
tein, a well-known inflammation marker, was associated* Correspondence: e.raffetti@unibs.it
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meta-analyses [2–4].
In HIV infected subjects, the incidence of non-AIDS
related chronic disorders, particularly cancer, has in-
creased in last decade, even in those with long-term
antiretroviral therapy (ART), and it is now higher than
the general population [5, 6], possibly due to residual
chronic immune activation and inflammation [7–10].
Indeed, higher levels of several inflammatory biomarkers
have been found to be associated with increased risk of
AIDS and non-AIDS events, including cancer in these
patients [11, 12].
The identification of predictors of cancer incidence in
HIV-positive subjects in usual care would be useful tois distributed under the terms of the Creative Commons Attribution 4.0
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these events. The neutrophil to lymphocyte ratio (NLR)
and platelet to lymphocyte ratio (PLR) are low cost,
routine available, inflammatory indices, which have been
demonstrated useful for predicting risk of death in patients
with solid cancer in the general population, independently
of tumor characteristics [13–15]. In a previous study among
HIV-infected subjects, we found that NLR and PLR serum
values were predictive of risk of death in subjects with solid
non-AIDS defining cancer (NADC), though not in
those with solid AIDS defining cancer (ADC) [16].
However, no study evaluated the possible use of NLR
and PLR for predicting cancer incidence in HIV-positive
subjects, or in the general population, so far, to our
knowledge.
The aim of our study was to assess the association of
PLR and NLR with risk of solid NADC in a multicenter
cohort of HIV-infected subjects.Methods
We conducted a retrospective cohort study of HIV-infected
patients of the MASTER cohort in follow-up from January
2000 to December 2012, either ART naive or experienced.
Inclusion criteria were: age of 18 years and over, and no
solid NADC diagnosis before baseline. The baseline was 1st
January 2001 for subjects enrolled in MASTER cohort be-
fore that date, and the date of enrollment in the cohort for
patients who entered in the cohort after that date. The
characteristics of the MASTER cohort and the procedures
of cancer data collection have been described elsewhere
[17]. The following data were retrieved from the electronic
database: gender, age, country of origin, HIV exposure
group, date of enrolment in the cohort, viral hepatitis C
or B co-infection, ART, AIDS event and cancer occur-
rence. Moreover, the following parameters, measured
within 6 months from the diagnosis of cancer, were re-
trieved: HIV-RNA, CD4 cell count, CD8 cell count, neu-
trophil, lymphocyte and platelet count.
The inflammatory factors evaluated were NLR and
PLR, considered as continuous and dichotomized according
to their median.
The primary outcome was the incidence of NADCs,
which were coded according to the international classifi-
cation of diseases (ICD), 9th and 10th revisions [18].
Hematological cancers (ICD-10 code, from 81 to 96)
and solid ADCs (Kaposi sarcoma and invasive cervical
carcinoma, ICD-10 code 46 and 53, respectively) were
excluded from the analysis.
The study was conducted in accordance with the guide-
lines of the Declaration of Helsinki and the principles of
Good Clinical Practice. The study protocol was approved
by the local ethics committees. Informed consent was
obtained by all patients enrolled.Statistical analysis
Observation time was calculated from study inclusion
until cancer occurence, death, last follow-up visit or 31st
December 2012.
The differences in demographic, clinical and pathological
features between losses to follow-up and non-losses to
follow-up were tested using common statistical methods
for median and proportion comparisons.
The age- and gender-adjusted NADC incidence rates
were calculated dividing the number of observed cases
by the corresponding person-years at risk, using the dir-
ect method of standardization, truncated at 65 years-old,
with the European population as the standard, according
to calendar period [19]. All the rates were expressed per
1000 person-years.
The associations of NLR, PLR with cancer incidence
were evaluated by univariate and multivariate analysis
using both time independent and time dependent Cox
proportional hazard models, which provided estimates of
hazard ratios (HRs), their 95 % confidence intervals (95 %
CIs) and p-values. In time dependent regression models,
the study period was divided into intervals of 1-year dur-
ation. Gender, age at enrolment, intravenous drug use and
hepatitis C or B virus co-infection were included in the
model as fixed covariates. NLR, PLR and CD4 cell count
were included as time-dependent covariates.
To evaluate whether the associations of NLR and PLR
with risk of cancer were not linear, we also fitted time
dependent Cox models with a cubic-spline for NLR and
PLR, respectively. We used the Akaike’s information criter-
ion to assess fitting of the models with linear and non-
linear terms and to choose the number of spline knots.
Finally, we conducted sensitivity analyses. Particularly,
we assessed the relations between NRL and PLR and cancer
incidence i) using competing risk regression models with
death from all causes as a competing event, ii) applying
inverse probability weighted methods in order to adjust
for selection bias due to losses to follow-up, iii) applying
inverse probability weighted methods in order to adjust for
selection bias due to missing values, iv) limiting the ana-
lysis to subjects enrolled from 1st January 2000, v) ex-
cluding the first year of follow-up; subjects who had
diagnosis of NADC within 1 year were not included in
such analysis, while the follow-up started 1 year later
for everyone else, vi) using 1:1 nested case—control de-
sign matched on age, gender, date of enrolment and
late presentation. The proportional hazards assumption
was investigated for each covariate and globally by ana-
lyzing Schoenfeld residuals. We first produced the
graphical plots and then carried out formal statistical tests
of their independence over the rank transformation of
time, but no departures from this assumption were found.
For statistical tests, P values lower than 0.05 were consid-
ered significant in two-tailed tests. All the computations
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puter, version 12.0 (StataCorp, College Station, TX, USA).
Results
A total of 13,559 HIV-positive subjects were included
(73.3 % males, mean age ± standard deviation (SD) =36.0 ±
10.0) contributing 88,700.2 person-years (median 6.3 years
of follow-up).
The patients’ characteristics at baseline are shown in
Table 1. Hepatitis B or/and C virus co-infection were
present in 43.4 %; 35.4 % of patients had intravenous
drug use as risk factor for HIV infection acquisition,
33.4 % of patients was assuming ART and 25.8 % had
undetectable HIV RNA (≤37 cp/ml). The median values
(interquartile range) of NLR and PLR were 1.5 (1–2.2)
and 109.9 (79.6–155.3), respectively.
The cumulative probability of loss to follow-up at
3 years was 15.3 % (95 % CI, 14.6–15.9 %). Patients lostTable 1 Patients’ characteristics at baseline
Characteristics n (%)
(n = 13,559)
Age, in years, median (IQR) 34.6 (28.4–41.8)
Male 9937 (73.3)
Immigrant 1667 (12.3)
Intravenous drug use 4799 (35.4)
HBV/HCV co-infection 5890 (43.4)
HIV-RNA viral load undetectable 3082 (25.8)
ART 4532 (33.4)











Lymphocytes, median (IQR) 1856 (1361–2390)
Neutrophils, median (IQR) 2694 (2000–3619)
Platelets, median (IQR) 210,999 (166,000–260,000)
NLR, median (IQR) 1.47 (1.03–2.17)
PLR, median (IQR) 109.9 (79.6–155.3)
Missing values: Immigrant 81 (0.6 %); HIV-RNA viral load undetectable 1609
(11.9 %), CD4 cell count 1552 (11.5 %), CD4/CD8 7981 (58.9 %), Lymphocytes
2607 (19.2 %); Neutrophils 4023 (29.7 %); Platelets 2553 (18.8 %); NLR 4978
(36.7 %); PLR 3107 (22.9 %)
IQR interquartile range, HBV hepatitis B virus, HCV hepatitis C virus, ART
antiretroviral therapy, NLR neutrophil to lymphocytes ratio, PLR platelets to
lymphocytes ratioto follow-up, compared to those non-lost to follow-up,
had a higher proportion of immigrants (21.1 % vs
10.9 %), intravenous drugs users (39.6 % vs 34.7 %), a
lower proportion of HBV or HCV co-infection (35.4 %
vs 44.8 %) and of subjects undergoing ART (26.1 % vs
34.6 %), and lower lymphocytes and platelets medians
(Additional file 1: Table S1).
During the follow-up, 337 subjects had a first diagno-
sis of solid NADC, mainly in the liver (n = 75, 22.3 %),
lung (n = 33, 9.8 %), rectum and anus (n = 27, 8.0 %)
breast (n = 25, 7.4 %) and cutaneous melanoma (n = 17,
5.0 %) (Additional file 1: Table S2). The crude age- and
gender-standardized incidence rates were 3.57 and 3.91
per 1000 person-years, respectively.
The predictive role of PLR and NLR for NADC incidence
using time independent and time dependent Cox regression
models is shown in Table 2. At univariate analysis, NLR
showed no association with cancer incidence using time in-
dependent models, whereas it was associated with cancer
risk when it was included as a continuous or dichotomized
(higher than as compared to less than 1.47) variable in time
dependent models. However, the association was not con-
firmed when fitting a multivariate time dependent model
including also age, gender, CD4 cell count, presence of
Hepatitis B or/and C virus co-infection and intravenous
drug use. No association was found between PLR and can-
cer incidence using both time independent and time
dependent models, when also considering PLR as continu-
ous. Using a multivariate model, older age, presence of
Hepatitis B or/and C virus co-infection and lower CD4 cell
count were associated with solid NADC incidence (Add-
itional file 1: Table S3).
NLR and PLR were also evaluated in multivariate
time-independent Cox regression models with restricted
cubic-splines for these variables, which showed a mod-
est, though not statistically significant increase of the
hazard ratio for cancer with increasing serum values of
the biomarkers (Fig. 1).
The results of the following sensitivity analyses were
consistent with previous findings: (i) applying competing
risk models, (ii) weighting models for losses to follow-up
and (iii) missing values, (iv) limiting the analysis to pa-
tients enrolled after 2000 and naïve to antiretroviral
therapy (6918 patients enrolled, with 123 NADC cases
first diagnosed in follow-up), (v) excluding the first year
of follow-up and (vi) using nested case—control design.Discussion
We did not observe an association between NLR and PLR
serum levels and risk of solid NADC in HIV-infected
patients after adjusting for age, gender, CD4 cell count,
presence of HBV and or HCV co-infection and intravenous
drug use. Both NLR and PLR values measured at baseline
Table 2 Associations of neutrophils to lymphocytes ratio and platelets to lymphocytes ratio with incidence of non-AIDS defining
cancer using Cox proportional regression models
Time independent model Time dependent model
Univariate Multivariate Univariate Multivariate
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
NLR
1.47≤ vs >1.47 0.93 0.72–1.21 0.93 0.71–1.21 1.29 1.02–1.63 1.06 0.84–1.35
Continuous 1.03 0.93–1.14 1.03 0.93–1.14 1.14 1.08–1.21 1.06 0.99–1.15
PLR
109.9≤ vs >109.9 0.83 0.66–1.05 0.81 0.64–1.04 0.98 0.77–1.22 0.78 0.61–1.01
Continuous 0.999 0.998–1.001 0.999 0.997–1.001 1.000 0.999–1.002 0.999 0.997–1.001
HR hazard ratio, 95 % CI 95 % confidence interval, NLR neutrophils to lymphocytes ratio, PLR platelets to lymphocytes ratio
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development.
Chronic inflammation is believed to promote carcino-
genesis and therefore to increase the risk of developing
cancer. In last decade, several cohort studies among
healthy people evaluated various inflammation markers,
mainly interleukin-6 (IL-6), C-reactive protein (CRP),
and tumor necrosis factor-α (TNF-α), as predictive of
risk of overall cancer and particularly colorectal, breast,
lung, liver and prostate cancer, with inconsistent findings
[2–4, 20–26]. The different role of these biomarkers in
the inflammation process, the single measurement of
them in time, the relatively short follow-up of some
studies are possible explanations for these discrepancies.
Furthermore, some authors found that only a small
part of the total inflammation biomarkers tested wasFig. 1 Hazard ratios (HRs) of non-AIDS defining cancer using cubic spline t
to lymphocytes ratio (PLR) with three knots in Cox regression model. The refe
shown as dashed lines. Vertical axes are on a logarithmic scale. Abbreviations:
lymphocytes ratioassociated with risk of cancer and proposed a combina-
tion of some of them in a predictive score [26]. There-
fore, the negative findings of our study on the possible
predictive role of NLR and PLR in HIV positive subjects,
who may suffer from chronic inflammation due to their
disease and treatment, when also considering repeated
measures of these biomarkers during follow-up, are not
really surprising compared to the mentioned studies. It
is of note, however, that no study investigated the role of
NLR and PLR as predictors of cancer risk in the general
population so far, to our knowledge.
In our study we could not evaluate the association of
NLR and PLR with incidence of specific cancer types or
sites because of the relatively small number of patients
who developed cancer in the follow-up, mainly due to the
low mean age of HIV patients at enrollment and relativelyerms (solid lines) for neutrophils to lymphocytes ratio (NLR) and platelets
rence values are 1.5 and 110, respectively. The 95 % confidence limits are
HR, hazard ratio; NLR, neutrophils to lymphocytes ratio; PLR, platelets to
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Therefore, our findings do not exclude the possibility
that the levels of these inflammatory markers may be
predictive of the risk of HIV positive subjects to develop
specific neoplasms.
The main strengths of this study are: (i) the fair size of
the cohort for evaluating risk of overall cancer, (ii) the
completeness of data on cancer occurrence, (iii) the lack
of selection in patients included in the cohort, which
provides an unbiased “real world” scenario of the clinical
practice and epidemiological pattern of HIV infection
and AIDS disease throughout Italy, (iv) the availability
of repeated measures of NLR and PLR in time, and (v)
the analysis of time dependent and time independent
regression models for evaluating these biomarkers at
baseline and during the follow-up. This study has some
limits, too, mainly the small number of cancer cases,
the lack of data on the main risk factors for cancer and
on the clinical stage or other parameters of severity of
cancer at diagnosis.
Around one third of the subjects (36 %) were lost to
follow-up at 3 years. They differed from those unlost for
various characteristics. However, there were no significant
differences either in the variables predictive of cancer risk
by multivariate model apart from HBV/HCV coinfection,
or in NLR or PLR values. Therefore, it is unlikely that loss
to follow-up may have caused bias in the main findings of
our study.
Conclusions
This study does not sustain the hypothesis that NRL and
PLR, two simple and low-cost inflammatory parameters
associated with risk of death in people with cancer, may be
also useful to predict cancer occurrence in HIV positive
subjects.
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